Zhiyang Lv

Zhiyang Lv

Auto-generated profile, based on publicly available information

Zhiyang Lv

School of Pharmacy, Jiangsu Food and Pharmaceutical Science College, Huaian 223003, People's Republic of China

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 November 2022 in Biomedicine & Pharmacotherapy
Verified
Journal Article
Open access
JCJing Chen
Jing Chen
ZOZhijie Ou
Zhijie Ou
TGTiantian Gao
Tiantian Gao
YYYuwei Yang
Yuwei Yang
ASAnmei Shu
Anmei Shu
ZLZhiyang Lv
Zhiyang Lv
Diabetic nephropathy (DN) is the leading cause of end‑stage renal disease. Although Ginkgo biloba extract has a protective effect on DN, the protective effect and mechanism of its active ingredient Ginkgolide B (GB) on DN remain unclear. The aim of the present study was to investigate whether GB improves DN via alleviating oxidative stress and ferroptosis by inhibiting GPX4 ubiquitination in PA-G-induced mouse podocytes and DN mice. The study in vitro showed that GB effectively reduced serum total cholesterol, triglyceride concentrations and lipid accumulation in PA-G-induced MPC5 cells. In addition, GB promoted the expression of ferroptosis markers GPX4 and FTH1, while inhibited the expression of TfR1, fibrosis markers α-SMA and Collagen α1, as well as intracellular iron content and ROS levels. Interference of GPX4 expression with siRNA counteracted the effect of GB. And GB inhibited GPX4 ubiquitination in a dose-dependent manner. In vivo the experimental results showed that GB effectively reduced hyperglycemia, serum total cholesterol and triglyceride concentrations, reduced urinary albumin excretion and the number of renal lipid droplets, and improved changes in renal structure in DN mice. GB inhibited the expression of ferroptosis marker TfR1 and fibrosis markers α-SMA and Collagen α1, while promoted the expression of ferroptosis markers GPX4 and FTH1. In conclusion, the results suggested that GB may improve DN via protecting the kidney from ferroptosis and oxidative stress damage by inhibiting the ubiquitination of GPX4. These findings suggested that GB, a natural medicine, may be an effective therapeutic option for DN.

1 December 2020 in Toxicology
Verified
Journal Article
Closed access
YYYuwei Yang
Yuwei Yang
JCJing Chen
Jing Chen
QGQin Gao
Qin Gao
XSXin Shan
Xin Shan
JWJie Wang
Jie Wang
ZLZhiyang Lv
Zhiyang Lv

1 January 2021 in Oxidative Medicine and Cellular Longevity
Verified
Journal Article
Open access
PDF file
XSXin Shan
Xin Shan
ZLZhi-Yang Lv
Zhi-Yang Lv
MYMeng-Jiao Yin
Meng-Jiao Yin
JCJing Chen
Jing Chen
JWJie Wang
Jie Wang
QWQinan Wu
Qinan Wu
This study was conducted to estimate the protective effect of Cyanidin‐3‐glucoside (C3G) on myocardial ischemia‐reperfusion (IR) injury and to explore its mechanism. The rats were subjected to left anterior descending ligation and perfusion surgery. In vitro experiments were performed on H9c2 cells using the oxygen‐glucose deprivation/reoxygenation (OGD/R) model. The results showed the administration of C3G reduced the infarction area, mitigated pathological alterations, inhibited ST segment elevation, and attenuated oxidative stress and ferroptosis‐related protein expression. C3G also suppressed the expressions of USP19, Beclin1, NCOA4, and LC3II/LC3I. In addition, treatment with C3G relieved oxidative stress, downregulated LC3II/LC3I, reduced autophagosome number, downregulated TfR1 expression, and upregulated the expressions of FTH1 and GPX4 in OGD/R‐induced H9c2 cells. C3G could inhibit the protein levels of USP19 and LC3II. C3G promoted K11‐linked ubiquitination of Beclin1. Further evidence that C3G reduced ferroptosis and ameliorated myocardial I/R injury was demonstrated with the ferroptosis promoter RSL3. Taken together, C3G could be a potential agent to protect myocardium from myocardial I/R injury.

1 September 2020 in Life Sciences
Verified
Journal Article
Closed access
JCJing Chen
Jing Chen
YYYuwei Yang
Yuwei Yang
ZLZhiyang Lv
Zhiyang Lv
ASAnmei Shu
Anmei Shu
QDQiu Du
Qiu Du
HXHuiqin Xu
Huiqin Xu

2 December 2020 in Journal of Diabetes Research
Verified
Journal Article
Open access
PDF file
JCJing Chen
Jing Chen
YCYuping Chen
Yuping Chen
ASAnmei Shu
Anmei Shu
JLJinfu Lu
Jinfu Lu
QDQiu Du
Qiu Du
HXHuiqin Xu
Huiqin Xu
Background and Aims. Radix Rehmanniae and Corni Fructus (RC) have been widely applied to treat diabetic nephropathy (DN) for centuries. But the mechanism of how RC plays the therapeutic role against DN is unclear as yet. Methods. The information about RC was obtained from a public database. The active compounds of RC were screened by oral bioavailability (OB) and drug-likeness (DL). Gene ontology (GO) analysis was performed to realize the key targets of RC, and an active compound-potential target network was created. The therapeutic effects of RC active compounds and their key signal pathways were preliminarily probed via network pharmacology analysis and animal experiments. Results. In this study, 29 active compounds from RC and 64 key targets related to DN were collected using the network pharmacology method. The pathway enrichment analysis showed that RC regulated advanced glycosylation end product (AGE-) RAGE and IL-17 signaling pathways to treat DN. The animal experiments revealed that RC significantly improved metabolic parameters, inflammation renal structure, and function to protect the kidney against DN. Conclusions. The results revealed the relationship between multicomponents and multitargets of RC. The administratiom of RC might remit the DM-induced renal damage through the AGE-RAGE signaling pathway to improve metabolic parameters and protect renal structure and function.

31 March 2026 in Brain Research Bulletin
Verified
Journal Article
Open access
ZLZhiyang Lv
Zhiyang Lv
ZJZhiping Ji
Zhiping Ji
JCJing Chen
Jing Chen
TLTianning Long
Tianning Long
HNHongyun Niu
Hongyun Niu
YYYuwei Yang
Yuwei Yang
This study investigates the protective effect of GB against cerebral I/R injury and explores its underlying mechanism involving the TRIM45- TAB2-TAK1-TAB1 axis. In vivo, a tMCAO rat model was used. Relevant groups were treated with GB, and indicators including neurological function, cerebral infarct volume, and blood-brain barrier (BBB) integrity were detected, with Edaravone as a positive control. In vitro, oxygen-glucose deprivation/reperfusion (OGD/R)-induced BV2 cells were employed. Cell viability, inflammatory response, and protein expression were tested in the cells treated with or without GB. For mechanistic validation, TRIM45 overexpression and TRIM45 knockdown experiments were performed in BV2 cells. Additionally, molecular docking was conducted to predict the binding mode between GB and TRIM45. GB dose-dependently improved rat neurological function, reduced infarct volume/edema, inhibited apoptosis, and lowered IL-1β/IL-6/TNF-α levels. Mechanistically, GB downregulated TRIM45 expression, reduced K63-linked ubiquitination of TAB2, disrupted TAB2-TAK1-TAB1 complex formation, and blocked NF-κB pathway activation. Molecular docking revealed that GB directly binds to pocket 279 of TRIM45. Functional studies further confirmed the necessity of TRIM45 in GB's action: TRIM45 overexpression reversed the regulatory effects of GB on TAB2 ubiquitination, inflammatory cytokine production, and NF-κB activation, whereas TRIM45 knockdown mimicked and enhanced GB's anti-inflammatory effects. These gain-of-function and loss-of-function experiments mutually validate that GB exerts its neuroprotective effects against cerebral ischemia-reperfusion injury by targeting the TRIM45-related pathway. Our findings show that GB protects against cerebral ischemia-reperfusion injury by targeting TRIM45 to disrupt the TRIM45-TAB2-TAK1-TAB1 complex and inhibit NF-κB-mediated neuroinflammation. GB holds potential for treating this injury, warranting further mechanistic studies and clinical trials to support its clinical translation.